Document Detail

Role of a non-hormonal oral anti-fibrinolytic hemostatic agent (tranexamic acid) for management of patients with dysfunctional uterine bleeding.
MedLine Citation:
PMID:  19860359     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Perimenaposal dysfunctional bleeding is a common complaint seen in gynecology clinics. Tranexamic acid is a cheap, over the counter hemostatic agent with antifibrinolytic activity that can be used for management of excessive menstrual bleeding. However, there are few reports analyzing its effectiveness in the management of abnormal menstrual bleeding. This study aimed to evaluate the effectiveness of oral transexamic acid treatment in patients with excessive dysfunctional perimenopausal menorrhagia. METHOD: One hundred and thirty-two consecutive patients with dysfunctional perimenepausal uterine bleeding who were admitted to Cankiri Government Hospital between March 2007 and January 2008 were prospectively enrolled into this one-sided study. All the patients were asked to fill out menstrual diaries and to come to follow-up three months after the initial evaluation. All patients took 500 mg of transexamic acid (Transamine 3x2) during their menses as the primary treatment and iron preparations if Hb was < 10 g/dl. The paired sample t-test was used for statistical evaluation. RESULTS: Mean age of the patients was 42.8 (range 38-46 yrs). Median bleeding time was nine days (range 8-12 days) and median Hb was 10.6 g/dl (range 8.2-11.7) before starting the treatment. During follow-up 45 patients were unresponsive to transamine and needed further treatments (overall response rate was 65.9%). Among responsive patients, after three cycles of transamine usage median bleeding time was five days (range 3-8 days) and median Hb values were 12.1 g/dl. CONCLUSION: Oral tranexamic acid is a reasonable treatment option for patients with excessive dysfunctional perimenopousal bleeding with a 66.0% response rate.
M Gultekin; K Diribaş; E Buru; M A Gökçeoğlu
Related Documents :
9345199 - Conservative treatment of hemarthrosis for prevention of hemophilic synovitis.
20129389 - Immunoadsorption in the treatment of acquired haemophilia.
9007429 - Injection of fibrin tissue adhesive versus laser photocoagulation in the treatment of h...
16911649 - Topical adrenaline in the control of intraoperative bleeding in adenoidectomy: a random...
1858759 - Same-day upper and lower inpatient endoscopy: a trend for the future.
17253129 - Endoscopic removal of large sessile colorectal adenomas: is it safe and effective?
8730249 - Triple therapy with sucralfate, amoxycillin and metronidazole for healing duodenal ulce...
22544779 - The older worker with osteoarthritis of the knee.
8989709 - Hemivertebral excision for congenital scoliosis.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Clinical and experimental obstetrics & gynecology     Volume:  36     ISSN:  0390-6663     ISO Abbreviation:  Clin Exp Obstet Gynecol     Publication Date:  2009  
Date Detail:
Created Date:  2009-10-28     Completed Date:  2009-12-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7802110     Medline TA:  Clin Exp Obstet Gynecol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  163-5     Citation Subset:  IM    
Department of Obstetrics and Gynecology, Cankiri Government Hospital, Cankiri, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Antifibrinolytic Agents / therapeutic use*
Metrorrhagia / drug therapy*
Middle Aged
Tranexamic Acid / therapeutic use*
Reg. No./Substance:
0/Antifibrinolytic Agents; 1197-18-8/Tranexamic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Analysis of federal process of care data reported from hospitals in rural westernmost North Carolina...
Next Document:  Disturbed sleep and preterm birth: a potential relationship?